Catalent to buy Paragon Bioservices for $1.2 billion: WSJ

(Reuters) – Drug developer Catalent Inc has agreed to buy privately held Paragon Bioservices Inc for $1.2 billion, the Wall Street Journal reported on Sunday, citing people familiar with the matter.

An all-cash deal between the companies is expected to be announced on Monday morning, the Journal.

Reporting by Ismail Shakil in Bengaluru; Editing by Chris Reese